Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Teladoc Health (TDOC) but lowers the price target from $34 to $28.
February 21, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Teladoc Health but lowers the price target from $34 to $28.
While the maintenance of a Buy rating suggests continued confidence in Teladoc Health's fundamentals and future prospects, the reduction in the price target could indicate concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for TDOC shares, but the overall positive stance could mitigate negative impacts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100